Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Daiichi Sankyo.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
155actual
Sites
42
Countries
Belgium, Italy, Japan +5
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-02-02 | actual | When the study began enrolling |
| Primary completion | 2026-05-04 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-05-04 | estimated | The whole study's end, after follow-up |
| First posted | 2020-11-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Advanced or Metastatic NSCLC
Interventions
- Drug: Datopotamab deruxtecan — also filed as Dato-DXd
- Drug: Durvalumab — also filed as Imfinzi
- Drug: Carboplatin
- Drug: AZD2936 — also filed as rilvegostomig
- Drug: MEDI5752 — also filed as volrustomig
- Drug: AZD7789 — also filed as sabestomig
Primary outcome
what the primary-completion date above is the date OFNumber of participants with DLTs; TEAEs and other safety parameters during the study.
measured DLTs: within first cycle (21 days); TEAEs and other safety parameters: when all participants have either discontinued the study or the last participant enrolled in the study has completed at least 9 months of follow-up (approximately 60 months)
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed